Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omacetaxine with 7+3 Induction in Newly Diagnosed AML
NCT02440568Phase 2Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Jun 2015
- Primary completion
- Nov 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of homoharringtonine in acute myeloid leukemia (AML), sponsored by University of Illinois Chicago. Started Jun 2015; status: terminated.
02
Drugs
homoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02440568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440568.